Overall Goals of the Cancer Moonshot

• Accelerate progress in cancer, including prevention & screening
  • From cutting edge research to wider uptake of standard of care
• Encourage greater cooperation and collaboration
  • Within and between academia, government, and private sector
• Enhance data sharing

(Presidential Memo 2016)
Blue Ribbon Panel Goals

• Identify major scientific opportunities that are poised to be accelerated by additional emphasis and funding

• *Develop recommendations of opportunities that would be pursued through the Cancer Moonshot*
  
  • *Final recommendations at www.cancer.gov/brp*
Blue Ribbon Panel Recommendations

A. Network for direct patient engagement
B. Cancer immunotherapy translational science network
C. Therapeutic target identification to overcome drug resistance
D. Creation of a national cancer data ecosystem
E. Fusion oncoproteins in pediatric cancer
F. Symptom management research
G. Precision prevention and early detection
H. Retrospective analysis of biospecimens from patients treated with standard of care
I. Creation of human tumor atlas
J. Development of new enabling technologies

Cross Cutting Themes: Health disparities, prevention, technology development, data sharing, partnerships

www.cancer.gov/brp
Cancer Funding in 21st Century Cures Act

- The cancer research portion is named the Beau Biden Cancer Moonshot Initiative
- $1.8 billion over 7 years
  - $300 million for FY17
- “To support cancer research, such as the development of cancer vaccines, the development of more sensitive diagnostic tests for cancer, immunotherapy and the development of combination therapies, research that has the potential to transform the scientific field that has inherently higher risk, and that seeks to address major challenges associated with cancer.”
FY17 Implementation of Blue Ribbon Panel Recommendations: Laying the Groundwork

- Fusion Oncoproteins in pediatric cancer
  - Gene Fusions in Pediatric Sarcomas (APRC)
- New Enabling Technologies
  - APTRC supplement program
  - Advancing new enabling technologies in cancer research
  - PDX development centers
- Cancer Immunotherapy
  - Biomarker development labs (CIMAC) for adult and pediatric;
  - Canine immunotherapy
  - Expand CIMAC to include pediatrics
  - Autoimmune sequelae – with NIAID
- Therapeutic Target Identification to Overcome Drug Resistance
- Prevention and Early Detection
  - HPV trial
  - Tobacco cessation supplements to Cancer Centers
- Symptom Management Research
  - Oral anticancer agents
Beyond FY17: FY18 and FY19

Implementation of Blue Ribbon Panel Recommendations
Process for Implementation of BRP Recommendations

- SPL
- Implementation Steering Committee
- Implementation Coordinating Committee
- Implementation Partnership Committee
- Cancer Moonshot Implementation Teams Aligned with BRP Recommendations
Charge to Cancer Moonshot Implementation Teams

• Discuss approaches and develop initiatives for FY18 and FY19 that will achieve the goals of the Recommendation
  • Identify gaps and opportunities in current landscape of existing initiatives
  • Seek input from others, including the cancer research community, advocates, and associations
  • Work with the Partnership Committee to consider creating and/or leveraging partnerships (academia, industry, pharma, ...)
• Provide oversight and coordination of the Team’s funded initiatives (e.g. managing awards, organizing meetings, providing supplements)
Process for Implementation of BRP Recommendations

- SPL
- Implementation Steering Committee
- Implementation Coordinating Committee
- Implementation Partnership Committee

Cancer Moonshot Implementation Teams (CMIT) Aligned with BRP Recommendations
Questions
Questions?

https://cancer.gov/BRP

National Cancer Advisory Board
February 15, 2017
FY17 Implementation of Blue Ribbon Panel Recommendations: Laying the Groundwork

- Fusion Oncoproteins in pediatric cancer
  - Gene Fusions in Pediatric Sarcomas (APRC) PA-17-138

- New Enabling Technologies
  - APTRC supplement program PA-17-143
  - Innovative and Applied Emerging Molecular Analysis Technologies in Cancer Research RFA-CA-17-010, 011, 012, 013
  - PDX development centers RFA-CA-17-003, 004

- Cancer Immunotherapy
  - Biomarker development labs (CIMAC) for adult and pediatric; RFA-CA-17-005, 006
  - Canine immunotherapy RFA-CA-17-001, 002
  - Expand CIMAC to include pediatrics NOT-CA-17-024, 025
  - Autoimmune sequelae – with NIAID (to be issued)

- Therapeutic Target Identification to Overcome Drug Resistance RFA-CA-17-009

- Prevention and Early Detection
  - HPV trial (DCEG-Gates Foundation)
  - Tobacco cessation supplements to Cancer Centers

- Symptom Management Research
  - Oral anticancer agents PA-17-060, 061
Funding for Beau Biden Cancer Moonshot

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Dollar in Millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$300</td>
</tr>
<tr>
<td>2018</td>
<td>$300</td>
</tr>
<tr>
<td>2019</td>
<td>$400</td>
</tr>
<tr>
<td>2020</td>
<td>$195</td>
</tr>
<tr>
<td>2021</td>
<td>$195</td>
</tr>
<tr>
<td>2022</td>
<td>$194</td>
</tr>
<tr>
<td>2023</td>
<td>$216</td>
</tr>
</tbody>
</table>

Beau Biden Cancer Moonshot Funding
Cancer Moonshot Implementation Teams

A. Network for Direct Patient Engagement
B. Cancer Immunotherapy Translational Science Network
   Bi. Pediatric Implementation Team
   Bii. Adult Implementation Team
C. Therapeutic Target Identification to Overcome Drug Resistance
D. A National Cancer Data Ecosystem for Sharing and Analysis
E. Fusion Oncoproteins in Childhood Cancers
F. Symptom Management Research
G. Prevention and Early Detection: Implementation and Evidenced-Based Approaches
   Gi. High Risk Cancers Implementation Team
   Gii. Cancer Prevention and Screening Implementation Team
H. Development of New Enabling Cancer Technologies
I. Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care
J. Generation of Human Tumor Atlases
Implementation Team Composition and Responsibilities

- NCI Extramural Program Staff
  - Responsible for developing LOI’s, concepts and initiatives for extramural funding
  - Responsible for developing funding plans and management of awards

- NCI Intramural Staff
  - Participate in a parallel intramural process for developing and vetting intramural LOIs
  - Present reviewed intramural proposals to incorporate into proposed funding plans

- Staff from other IC’s
  - Participate in the discussions, identifying areas of common interest and collaboration
  - Develop proposals for collaboration and propose sign-on to RFAs to parent IC

- NCI CRS staff
  - Will provide support for Wiki page, capturing key ideas and action items from Team meetings, portfolio analysis, and other scientific support activities